ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,430.41
0.59%
Dow Jones
39,387.76
0.85%
Gold vs US Dollar
2,368.535
0.92%
Brent Oil
83.905
-0.05%
Bitcoin
62,930.05
-0.19%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Grifols SA (GRFS)

  7. Grifols SA (GRFS) News

Grifols (GRFS)

Grifols SA
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:GRFS
DateTimeSourceHeadlineSymbolCompany
19/04/202421:42PR Newswire (US)Grifols 2023 Annual Report on Form 20-F filed with the SECNASDAQ:GRFSGrifols SA
18/04/202414:30GlobeNewswire Inc.Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.NASDAQ:GRFSGrifols SA
15/04/202412:06IH Market NewsSamsung Surpasses Apple in Q1 Smartphone Market; Salesforce in Talks to Acquire Informatica, and More NewsNASDAQ:GRFSGrifols SA
04/04/202409:00GlobeNewswire Inc.Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus ScreeningNASDAQ:GRFSGrifols SA
22/03/202413:07IH Market NewsFedEx Soars 13% with Profits Above Forecasts, Nike Hit by China Slowdown, and Latest NewsNASDAQ:GRFSGrifols SA
08/03/202411:19IH Market NewsCNOOC Oil Field Discovery in South China Sea, Grifols Surges 18% After KPMG Approval, and Latest NewsNASDAQ:GRFSGrifols SA
14/02/202408:16GlobeNewswire Inc.Grifols announces positive topline phase 3 fibrinogen clinical trial resultsNASDAQ:GRFSGrifols SA
26/01/202422:14Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
16/01/202411:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
12/01/202411:10IH Market NewsWall Street Highlights: DocuSign Acquisition Battle, Tesla Berlin Production Halt, and MoreNASDAQ:GRFSGrifols SA
10/01/202418:08Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
10/01/202413:59Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
10/01/202411:21IH Market NewsWall Street Highlights: Tesla Launches Restyled Model 3, VinFast Unveils Pickup Prototype, and MoreNASDAQ:GRFSGrifols SA
09/01/202419:49Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
09/01/202413:25Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
29/12/202314:59Dow Jones NewsGrifols Shares Rise on $1.76 Billion Sale of 20% Stake in Shanghai RAAS to Pay Down DebtNASDAQ:GRFSGrifols SA
29/12/202314:46Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
29/12/202314:40Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
16/11/202310:00PR Newswire (US)Grifols launches new solution to facilitate pre-transfusion compatibility testing in multiple myeloma patientsNASDAQ:GRFSGrifols SA
15/11/202313:00GlobeNewswire Inc.Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-in-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin DeficiencyNASDAQ:GRFSGrifols SA
06/11/202313:00GlobeNewswire Inc.GigaGen Presents IND-Enabling Data and Phase 1 Trial Strategy for its Novel Anti-CTLA-4 Oncology Drug Candidate, GIGA-564, at SITC 2023NASDAQ:GRFSGrifols SA
02/11/202317:25Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
24/10/202323:30GlobeNewswire Inc.Araclon Biotech Presents Positive Final Results from Phase 2 Clinical Study of ABvac40 Alzheimer’s Vaccine at CTADNASDAQ:GRFSGrifols SA
20/10/202313:36Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
19/10/202313:00GlobeNewswire Inc.GigaGen Granted Expansion of Contract with US Department of Defense to Develop Synthetic Human Antibody Treatments for Botulinum NeurotoxinsNASDAQ:GRFSGrifols SA
28/09/202313:00GlobeNewswire Inc.GigaGen Partners with the National Cancer Institute to Advance Oncology Drug Candidate GIGA-564NASDAQ:GRFSGrifols SA
01/08/202313:00GlobeNewswire Inc.Grifols Accelerates Healthcare Innovation with Google Cloud’s AI and AnalyticsNASDAQ:GRFSGrifols SA
27/07/202316:44Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
20/07/202313:15GlobeNewswire Inc.Grifols Achieves Positive Topline Results From Phase 4 Study of XEMBIFY® (immune globulin subcutaneous human-klhw) Evaluating Biweekly Dosing Option for PatientsNASDAQ:GRFSGrifols SA
18/07/202313:00GlobeNewswire Inc.Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated CirrhosisNASDAQ:GRFSGrifols SA
 Showing the most relevant articles for your search:NASDAQ:GRFS

Your Recent History

LSE
POS
Plexus
LSE
SFOR
S4 Capital
LSE
TERN
Tern
LSE
AAZ
Anglo Asian Mining
LSE
PET
Petrel Resources
LSE
CHLL
Chill Brands
LSE
GDR
Genedrive
LSE
SYME
Supply@me Capital
LSE
POLX
Polarean Imaging
LSE
BOO
Boohoo
LSE
AGL
Angle
LSE
UPS
LSE
GOLD
LSE
ITV
Itv
LSE
TYM
Tertiary Minerals
LSE
LLOY
Lloyds Banking
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved